COPD and squamous cell lung cancer: Aberrant inflammation and immunity is the common link

British Journal of Pharmacology

Volumn 173, Issue 4, 2016, Pages 638-648

  Bozinovski, Steven ^a,b   Vlahos, Ross ^a,b   Anthony, Desiree ^b   McQualter, Jonathan ^b   Anderson, Gary ^b   Irving, Louis ^c   Steinfort, Daniel ^c  

^a RMIT UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; PROTEINASE; REACTIVE OXYGEN METABOLITE; SERUM AMYLOID A;

ADAPTIVE IMMUNITY; CANCER SUSCEPTIBILITY; CARCINOGENICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL LUNG CARCINOMA; IMMUNITY; IMMUNOLOGY; LUNG TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNITY; INFLAMMATION; LUNG NEOPLASMS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84957440398     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13198     Document Type: Review

References (160)

1. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. (2012). Persistent systemic inflammation is associated with poor clinical outcomes in COPD: A novel phenotype. PLoS ONE 7: e37483.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors. Br J Pharmacol 170: 1676-1705.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
5. Allavena P, Sica A, Solinas G, Porta C, Mantovani A, (2008). The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages. Crit Rev Oncol Hematol 66: 1-9.
6. Anderson GP, Bozinovski S, (2003). Acquired somatic mutations in the molecular pathogenesis of COPD. Trends Pharmacol Sci 24: 71-76.
7. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. (1994). Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 272: 1497-1505.
8. Anthony D, Seow HJ, Uddin M, Thompson M, Dousha L, Vlahos R, et al. (2013). Serum amyloid A promotes lung neutrophilia by increasing IL-17A levels in the mucosa and gammadelta T cells. Am J Respir Crit Care Med 188: 179-186.
9. Anthony D, McQualter JL, Bishara M, Lim EX, Yatmaz S, Seow HJ, et al. (2014). SAA drives proinflammatory heterotypic macrophage differentiation in the lung via CSF-1R-dependent signaling. FASEB J 28: 3867-3877.
10. Araya J, Cambier S, Markovics JA, Wolters P, Jablons D, Hill A, et al. (2007). Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients. J Clin Invest 117: 3551-3562.
11. Barnes PJ, Shapiro SD, Pauwels RA, (2003). Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 22: 672-688.
12. Beckett EL, Stevens RL, Jarnicki AG, Kim RY, Hanish I, Hansbro NG, et al. (2013). A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis. J Allergy Clin Immunol 131: 752-762.
13. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737-744.
14. Bernhard D, Csordas A, Henderson B, Rossmann A, Kind M, Wick G, (2005). Cigarette smoke metal-catalyzed protein oxidation leads to vascular endothelial cell contraction by depolymerization of microtubules. FASEB J 19: 1096-1107.
15. de Boer WI, Hau CM, van Schadewijk A, Stolk J, van Krieken JH, Hiemstra PS, (2006). Expression of epidermal growth factors and their receptors in the bronchial epithelium of subjects with chronic obstructive pulmonary disease. Am J Clin Pathol 125: 184-192.
16. Bonnans C, Fukunaga K, Levy MA, Levy BD, (2006). Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury. Am J Pathol 168: 1064-1072.
17. Borchers MT, Wesselkamper SC, Curull V, Ramirez-Sarmiento A, Sanchez-Font A, Garcia-Aymerich J, et al. (2009). Sustained CTL activation by murine pulmonary epithelial cells promotes the development of COPD-like disease. J Clin Invest 119: 636-649.
18. Bozinovski S, Hutchinson A, Thompson M, Macgregor L, Black J, Giannakis E, et al. (2008). Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177: 269-278.
19. Bozinovski S, Vlahos R, Zhang Y, Lah LC, Seow HJ, Mansell A, et al. (2011). Carbonylation caused by cigarette smoke extract is associated with defective macrophage immunity. Am J Respir Cell Mol Biol 45: 229-236.
20. Bozinovski S, Uddin M, Vlahos R, Thompson M, McQualter JL, Merritt AS, et al. (2012). Serum amyloid A opposes lipoxin A(4) to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A 109: 935-940.
21. Bracke KR, Verhamme FM, Seys LJ, Bantsimba-Malanda C, Cunoosamy DM, Herbst R, et al. (2013). Role of CXCL13 in cigarette smoke-induced lymphoid follicle formation and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 188: 343-355.
22. Brusselle GG, Joos GF, Bracke KR, (2011). New insights into the immunology of chronic obstructive pulmonary disease. Lancet 378: 1015-1026.
23. Cetin K, Ettinger DS, Hei YJ, O'Malley CD, (2011). Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clin Epidemiol 3: 139-148.
24. Chang SH, Mirabolfathinejad SG, Katta H, Cumpian AM, Gong L, Caetano MS, et al. (2014). T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci U S A 111: 5664-5669.
25. Chen K, Pociask DA, McAleer JP, Chan YR, Alcorn JF, Kreindler JL, et al. (2011). IL-17RA is required for CCL2 expression, macrophage recruitment, and emphysema in response to cigarette smoke. PLoS ONE 6: e20333.
26. Chen K, Liu M, Liu Y, Yoshimura T, Shen W, Le Y, et al. (2013). Formylpeptide receptor-2 contributes to colonic epithelial homeostasis, inflammation, and tumorigenesis. J Clin Invest 123: 1694-1704.
27. Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, et al. (2010). Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 69: 348-354.
28. Chiang N, Serhan CN, Dahlen SE, Drazen JM, Hay DW, Rovati GE, et al. (2006). The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 58: 463-487.
29. Church DF, Pryor WA, (1985). Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect 64: 111-126.
30. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, de Beer FC, (1986). Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 261: 9644-9651.
31. Cooray SN, Gobbetti T, Montero-Melendez T, McArthur S, Thompson D, Clark AJ, et al. (2013). Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc Natl Acad Sci U S A 110: 18232-18237.
32. Cosio M, Ghezzo H, Hogg JC, Corbin R, Loveland M, Dosman J, et al. (1978). The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 298: 1277-1281.
33. Covey TM, Edes K, Coombs GS, Virshup DM, Fitzpatrick FA, (2010). Alkylation of the tumor suppressor PTEN activates Akt and beta-catenin signaling: A mechanism linking inflammation and oxidative stress with cancer. PLoS ONE 5: e13545.
34. Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R, Milzani A, (2006). Protein carbonylation, cellular dysfunction, and disease progression. J Cell Mol Med 10: 389-406.
35. Dalle-Donne I, Carini M, Orioli M, Vistoli G, Regazzoni L, Colombo G, et al. (2009). Protein carbonylation: 2,4-dinitrophenylhydrazine reacts with both aldehydes/ketones and sulfenic acids. Free Radic Biol Med 46: 1411-1419.
36. Damiano VV, Tsang A, Kucich U, Abrams WR, Rosenbloom J, Kimbel P, et al. (1986). Immunolocalization of elastase in human emphysematous lungs. J Clin Invest 78: 482-493.
37. De Santo C, Arscott R, Booth S, Karydis I, Jones M, Asher R, et al. (2010). Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol 11: 1039-1046.
38. Dehle FC, Mukaro VR, Jurisevic C, Moffat D, Ahern J, Hodge G, et al. (2013). Defective lung macrophage function in lung cancer ± chronic obstructive pulmonary disease (COPD/emphysema)-mediated by cancer cell production of PGE2? PLoS ONE 8: e61573.
39. Dekhuijzen PN, Aben KK, Dekker I, Aarts LP, Wielders PL, van Herwaarden CL, et al. (1996). Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 154: 813-816.
40. Dennis RJ, Maldonado D, Norman S, Baena E, Martinez G, (1996). Woodsmoke exposure and risk for obstructive airways disease among women. Chest 109: 115-119.
41. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. (2011). Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475: 106-109.
42. Di Stefano A, Caramori G, Gnemmi I, Contoli M, Vicari C, Capelli A, et al. (2009). T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol 157: 316-324.
43. Doe C, Bafadhel M, Siddiqui S, Desai D, Mistry V, Rugman P, et al. (2010). Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest 138: 1140-1147.
44. Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, Crown J, et al. (2012). Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer 131: 911-923.
45. Drilon A, Rekhtman N, Ladanyi M, Paik P, (2012). Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol 13: e418-e426.
46. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD, (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998.
47. El Kebir D, Jozsef L, Pan W, Wang L, Petasis NA, Serhan CN, et al. (2009). 15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am J Respir Crit Care Med 180: 311-319.
48. Erfani N, Mehrabadi SM, Ghayumi MA, Haghshenas MR, Mojtahedi Z, Ghaderi A, et al. (2012). Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer 77: 306-311.
49. Foo SY, Phipps S, (2010). Regulation of inducible BALT formation and contribution to immunity and pathology. Mucosal Immunol 3: 537-544.
50. Franklin WA, Gazdar AF, Haney J, Wistuba II, La Rosa FG, Kennedy T, et al. (1997). Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest 100: 2133-2137.
51. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. (2011). Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29: 2866-2874.
52. Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, et al. (2014). Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med 189: 832-844.
53. Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR, (2000). Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 164: 1663-1667.
54. Gong L, Cumpian AM, Caetano MS, Ochoa CE, De la Garza MM, Lapid DJ, et al. (2013). Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase. Mol Cancer 12: 154.
55. Gustafson AM, Soldi R, Anderlind C, Scholand MB, Qian J, Zhang X, et al. (2010). Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci. Transl. Med. 2: 26ra25.
56. Hanahan D, Weinberg RA, (2011). Hallmarks of cancer: The next generation. Cell 144: 646-674.
57. Hansen MJ, Chan SP, Langenbach SY, Dousha LF, Jones JE, Yatmaz S, et al. (2014). IL-17A and serum amyloid A are elevated in a cigarette smoke cessation model associated with the persistence of pigmented macrophages, neutrophils and activated NK cells. PLoS ONE 9: e113180.
58. He R, Sang H, Ye RD, (2003). Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 101: 1572-1581.
59. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K, et al. (2008). The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 10: 1349-1355.
60. Hodge G, Barnawi J, Jurisevic C, Moffat D, Holmes M, Reynolds PN, et al. (2014). Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-gamma by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells. Clin Exp Immunol 178: 79-85.
61. Hodge S, Matthews G, Mukaro V, Ahern J, Shivam A, Hodge G, et al. (2011). Cigarette smoke-induced changes to alveolar macrophage phenotype and function are improved by treatment with procysteine. Am J Respir Cell Mol Biol 44: 673-681.
62. Hoffmann D, Hoffmann I, El-Bayoumy K, (2001). The less harmful cigarette: A controversial issue. A tribute to Ernst L. Wynder. Chem Res Toxicol 14: 767-790.
63. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. (2004). The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350: 2645-2653.
64. Houghton AM, (2013). Mechanistic links between COPD and lung cancer. Nat Rev Cancer 13: 233-245.
65. Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, et al. (2010). Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med 16: 219-223.
66. Hsiao HM, Sapinoro RE, Thatcher TH, Croasdell A, Levy EP, Fulton RA, et al. (2013). A novel anti-inflammatory and pro-resolving role for resolvin D1 in acute cigarette smoke-induced lung inflammation. PLoS ONE 8: e58258.
67. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S, (1998). Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58: 1048-1051.
68. Ivanov S, Bozinovski S, Bossios A, Valadi H, Vlahos R, Malmhall C, et al. (2007). Functional relevance of the IL-23-IL-17 axis in lungs in vivo. Am J Respir Cell Mol Biol 36: 442-451.
69. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, (2011). Global cancer statistics. CA Cancer J Clin 61: 69-90.
70. Jonsson F, Yin L, Lundholm C, Smedby KE, Czene K, Pawitan Y, (2013). Low-dose aspirin use and cancer characteristics: A population-based cohort study. Br J Cancer 109: 1921-1925.
71. Kalathil SG, Lugade AA, Pradhan V, Miller A, Parameswaran GI, Sethi S, et al. (2014). T-regulatory cells and programmed death 1 + T cells contribute to effector T-cell dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 190: 40-50.
72. Keatings VM, Collins PD, Scott DM, Barnes PJ, (1996). Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 153: 530-534.
73. Khau T, Langenbach SY, Schuliga M, Harris T, Johnstone CN, Anderson RL, et al. (2011). Annexin-1 signals mitogen-stimulated breast tumor cell proliferation by activation of the formyl peptide receptors (FPRs) 1 and 2. FASEB J 25: 483-496.
74. Kirkham PA, Caramori G, Casolari P, Papi AA, Edwards M, Shamji B, et al. (2011). Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 184: 796-802.
75. Klemke M, Samstag Y, (2009). Molecular mechanisms mediating oxidative stress-induced T-cell suppression in cancer. Adv Enzyme Regul 49: 107-112.
76. Klemke M, Wabnitz GH, Funke F, Funk B, Kirchgessner H, Samstag Y, (2008). Oxidation of cofilin mediates T cell hyporesponsiveness under oxidative stress conditions. Immunity 29: 404-413.
77. Kranenburg AR, Willems-Widyastuti A, Mooi WJ, Saxena PR, Sterk PJ, de Boer WI, et al. (2005). Chronic obstructive pulmonary disease is associated with enhanced bronchial expression of FGF-1, FGF-2, and FGFR-1. J Pathol 206: 28-38.
78. Kunz LI, Lapperre TS, Snoeck-Stroband JB, Budulac SE, Timens W, van Wijngaarden S, et al. (2011). Smoking status and anti-inflammatory macrophages in bronchoalveolar lavage and induced sputum in COPD. Respir Res 12: 34.
79. Kuwahara I, Lillehoj EP, Lu W, Singh IS, Isohama Y, Miyata T, et al. (2006). Neutrophil elastase induces IL-8 gene transcription and protein release through p38/NF-{kappa}B activation via EGFR transactivation in a lung epithelial cell line. Am J Physiol Lung Cell Mol Physiol 291: L407-L416.
80. Laan M, Bozinovski S, Anderson GP, (2004). Cigarette smoke inhibits lipopolysaccharide-induced production of inflammatory cytokines by suppressing the activation of activator protein-1 in bronchial epithelial cells. J Immunol 173: 4164-4170.
81. Lee JM, Kim EK, Seo H, Jeon I, Chae MJ, Park YJ, et al. (2014). Serum amyloid A3 exacerbates cancer by enhancing the suppressive capacity of myeloid-derived suppressor cells via TLR2-dependent STAT3 activation. Eur J Immunol 44: 1672-1684.
82. Lee SY, Kang EJ, Hur GY, Jung KH, Jung HC, Lee SY, et al. (2006). Peroxisome proliferator-activated receptor-gamma inhibits cigarette smoke solution-induced mucin production in human airway epithelial (NCI-H292) cells. Am J Physiol Lung Cell Mol Physiol 291: L84-L90.
83. Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A, Downes CP, (2003). Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J 22: 5501-5510.
84. Li G, Zhao J, Peng X, Liang J, Deng X, Chen Y, (2012). The mechanism involved in the loss of PTEN expression in NSCLC tumor cells. Biochem Biophys Res Commun 418: 547-552.
85. Li Y, Cai L, Wang H, Wu P, Gu W, Chen Y, et al. (2011). Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2. Oncogene 30: 3887-3899.
86. Lim WT, Zhang WH, Miller CR, Watters JW, Gao F, Viswanathan A, et al. (2007). PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep 17: 853-857.
87. Liu K, Anderson GP, Bozinovski S, (2008a). DNA vector augments inflammation in epithelial cells via EGFR-dependent regulation of TLR4 and TLR2. Am J Respir Cell Mol Biol 39: 305-311.
88. Liu K, Gualano RC, Hibbs ML, Anderson GP, Bozinovski S, (2008b). Epidermal growth factor receptor signaling to Erk1/2 and STATs control the intensity of the epithelial inflammatory responses to rhinovirus infection. J Biol Chem 283: 9977-9985.
89. Liu L, Liu J, Wang Y, Dai S, Wang X, Wu S, et al. (2011). A combined biomarker pattern improves the discrimination of lung cancer. Biomarkers 16: 20-30.
90. Liu YS, Luo XY, Li QR, Li H, Li C, Ni H, et al. (2012). Shotgun and targeted proteomics reveal that pre-surgery serum levels of LRG1, SAA, and C4BP may refine prognosis of resected squamous cell lung cancer. J Mol Cell Biol 4: 344-347.
91. Lopez AD, Murray CC, (1998). The global burden of disease, 1990-2020. Nat Med 4: 1241-1243.
92. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. (2012). Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30: 2046-2054.
93. Maisonneuve E, Ducret A, Khoueiry P, Lignon S, Longhi S, Talla E, et al. (2009). Rules governing selective protein carbonylation. PLoS ONE 4: e7269.
94. Makris D, Tzanakis N, Damianaki A, Ntaoukakis E, Neofytou E, Zervou M, et al. (2008). Microsatellite DNA instability and COPD exacerbations. Eur Respir J 32: 612-618.
95. Malhotra D, Thimmulappa R, Navas-Acien A, Sandford A, Elliott M, Singh A, et al. (2008). Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am J Respir Crit Care Med 178: 592-604.
96. Mallia P, Footitt J, Sotero R, Jepson A, Contoli M, Trujillo-Torralbo MB, et al. (2012). Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 186: 1117-1124.
97. Malmberg KJ, Arulampalam V, Ichihara F, Petersson M, Seki K, Andersson T, et al. (2001). Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappaB activation. J Immunol 167: 2595-2601.
98. Mannino DM, Aguayo SM, Petty TL, Redd SC, (2003). Low lung function and incident lung cancer in the United States: data from the first National Health and Nutrition Examination Survey follow-up. Arch Intern Med 163: 1475-1480.
99. Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, Wiencke JK, et al. (2005). PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 36: 768-776.
100. Minna JD, Fong K, Zochbauer-Muller S, Gazdar AF, (2002). Molecular pathogenesis of lung cancer and potential translational applications. Cancer J 8 (Suppl. 1): S41-S46.
101. Mosser DM, Edwards JP, (2008). Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969.
102. Motz GT, Eppert BL, Wortham BW, Amos-Kroohs RM, Flury JL, Wesselkamper SC, et al. (2010). Chronic cigarette smoke exposure primes NK cell activation in a mouse model of chronic obstructive pulmonary disease. J Immunol 184: 4460-4469.
103. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG, (2011). High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 28: 682-688.
104. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. (2007). Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 13: 828-835.
105. Nakayama T, Church DF, Pryor WA, (1989). Quantitative analysis of the hydrogen peroxide formed in aqueous cigarette tar extracts. Free Radic Biol Med 7: 9-15.
106. Naylor EJ, Bakstad D, Biffen M, Thong B, Calverley P, Scott S, et al. (2007). Haemophilus influenzae induces neutrophil necrosis: A role in chronic obstructive pulmonary disease? Am J Respir Cell Mol Biol 37: 135-143.
107. Nowak D, Antczak A, Krol M, Pietras T, Shariati B, Bialasiewicz P, et al. (1996). Increased content of hydrogen peroxide in the expired breath of cigarette smokers. Eur Respir J 9: 652-657.
108. Ohnishi K, Takagi M, Kurokawa Y, Satomi S, Konttinen YT, (1998). Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 78: 1077-1087.
109. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P, (2009). Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 33: 118-126.
110. Ouyang W, Kolls JK, Zheng Y, (2008). The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28: 454-467.
111. Pao W, Girard N, (2011). New driver mutations in non-small-cell lung cancer. Lancet Oncol 12: 175-180.
112. Papayianni A, Serhan CN, Brady HR, (1996). Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J Immunol 156: 2264-2272.
113. Papi A, Casoni G, Caramori G, Guzzinati I, Boschetto P, Ravenna F, et al. (2004). COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. Thorax 59: 679-681.
114. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. (2005). A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133-1141.
115. Pastukh VM, Zhang L, Ruchko MV, Gorodnya O, Bardwell GC, Tuder RM, et al. (2011). Oxidative DNA damage in lung tissue from patients with COPD is clustered in functionally significant sequences. Int J Chron Obstruct Pulmon Dis 6: 209-217.
116. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, Committee GS, (2001). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163: 1256-1276.
117. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: An expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
118. Pesci A, Balbi B, Majori M, Cacciani G, Bertacco S, Alciato P, et al. (1998). Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J 12: 380-386.
119. Prause O, Bozinovski S, Anderson GP, Linden A, (2004). Increased matrix metalloproteinase-9 concentration and activity after stimulation with interleukin-17 in mouse airways. Thorax 59: 313-317.
120. Pryor WA, (1997). Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Environ Health Perspect 105 (Suppl. 4): 875-882.
121. Pryor WA, Stone K, (1993). Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann N Y Acad Sci 686: 12-27, discussion 27-18.
122. Purdue MP, Gold L, Jarvholm B, Alavanja MC, Ward MH, Vermeulen R, (2007). Impaired lung function and lung cancer incidence in a cohort of Swedish construction workers. Thorax 62: 51-56.
123. Rahman I, (2012). Pharmacological antioxidant strategies as therapeutic interventions for COPD. Biochim Biophys Acta 1822: 714-728.
124. Rahman I, Adcock IM, (2006). Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 28: 219-242.
125. Rahman I, van Schadewijk AA, Crowther AJ, Hiemstra PS, Stolk J, MacNee W, et al. (2002). 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166: 490-495.
126. Reppert S, Boross I, Koslowski M, Tureci O, Koch S, Lehr HA, et al. (2011). A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. Nat Commun 2: 600.
127. Retamales I, Elliott WM, Meshi B, Coxson HO, Pare PD, Sciurba FC, et al. (2001). Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 164: 469-473.
128. Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. (2015). Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol 16: 257-265.
129. Romeo MS, Sokolova IA, Morrison LE, Zeng C, Baron AE, Hirsch FR, et al. (2003). Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization. J Mol Diagn 5: 103-112.
130. Rutgers SR, Postma DS, ten Hacken NH, Kauffman HF, van Der Mark TW, Koeter GH, et al. (2000). Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 55: 12-18.
131. Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE, et al. (1998). CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157: 822-826.
132. Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO, (2014). Antioxidants accelerate lung cancer progression in mice. Sci Transl Med 6: 221ra215.
133. Schmielau J, Finn OJ, (2001). Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 61: 4756-4760.
134. Serhan CN, (2005). Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids 73: 141-162.
135. Serhan CN, Chiang N, Van Dyke TE, (2008). Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8: 349-361.
136. Shao MX, Nadel JA, (2005). Neutrophil elastase induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase C, reactive oxygen species, and TNF-alpha-converting enzyme. J Immunol 175: 4009-4016.
137. Shaykhiev R, Krause A, Salit J, Strulovici-Barel Y, Harvey BG, O'Connor TP, et al. (2009). Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J Immunol 183: 2867-2883.
138. Shaykhiev R, Otaki F, Bonsu P, Dang DT, Teater M, Strulovici-Barel Y, et al. (2011). Cigarette smoking reprograms apical junctional complex molecular architecture in the human airway epithelium in vivo. Cell Mol Life Sci 68: 877-892.
139. Shen N, Wang J, Zhao M, Pei F, He B, (2011). Anti-interleukin-17 antibodies attenuate airway inflammation in tobacco-smoke-exposed mice. Inhal Toxicol 23: 212-218.
140. Skillrud DM, Offord KP, Miller RD, (1986). Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med 105: 503-507.
141. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, et al. (2002). Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8: 1178-1184.
142. Soriano C, Mukaro V, Hodge G, Ahern J, Holmes M, Jersmann H, et al. (2012). Increased proteinase inhibitor-9 (PI-9) and reduced granzyme B in lung cancer: mechanism for immune evasion? Lung Cancer 77: 38-45.
143. Sporn MB, Liby KT, (2012). NRF2 and cancer: The good, the bad and the importance of context. Nat Rev Cancer 12: 564-571.
144. Stadtman ER, (1993). Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu Rev Biochem 62: 797-821.
145. Stampfli MR, Anderson GP, (2009). How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol 9: 377-384.
146. Stanescu D, Sanna A, Veriter C, Kostianev S, Calcagni PG, Fabbri LM, et al. (1996). Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 51: 267-271.
147. Su SB, Gong W, Gao JL, Shen W, Murphy PM, Oppenheim JJ, et al. (1999). A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med 189: 395-402.
148. Tang JM, He QY, Guo RX, Chang XJ, (2006). Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51: 181-191.
149. Ueda K, Jinbo M, Li TS, Yagi T, Suga K, Hamano K, (2006). Computed tomography-diagnosed emphysema, not airway obstruction, is associated with the prognostic outcome of early-stage lung cancer. Clin Cancer Res 12: 6730-6736.
150. Urbanowicz RA, Lamb JR, Todd I, Corne JM, Fairclough LC, (2010). Enhanced effector function of cytotoxic cells in the induced sputum of COPD patients. Respir Res 11: 76.
151. Vlahos R, Bozinovski S, (2013). Glutathione peroxidase-1 as a novel therapeutic target for COPD. Redox Rep 18: 142-149.
152. Vlahos R, Bozinovski S, (2014). Role of alveolar macrophages in chronic obstructive pulmonary disease. Front Immunol 5: 435.
153. Vlahos R, Bozinovski S, Jones JE, Powell J, Gras J, Lilja A, et al. (2006). Differential protease, innate immunity, and NF-kappaB induction profiles during lung inflammation induced by subchronic cigarette smoke exposure in mice. Am J Physiol Lung Cell Mol Physiol 290: L931-L945.
154. Vlahos R, Wark PA, Anderson GP, Bozinovski S, (2012). Glucocorticosteroids differentially regulate MMP-9 and neutrophil elastase in COPD. PLoS ONE 7: e33277.
155. Walsh DE, Greene CM, Carroll TP, Taggart CC, Gallagher PM, O'Neill SJ, et al. (2001). Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium. J Biol Chem 276: 35494-35499.
156. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. (2010). Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science translational medicine 2: 62ra93.
157. Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P, (2005). Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 23: 8959-8967.
158. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS, Timens W, (2005). Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 26: 835-845.
159. Wistuba II, Mao L, Gazdar AF, (2002). Smoking molecular damage in bronchial epithelium. Oncogene 21: 7298-7306.
160. Yang P, Sun Z, Krowka MJ, Aubry MC, Bamlet WR, Wampfler JA, et al. (2008). Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med 168: 1097-1103.